Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
50.52
+0.57 (+1.14%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,942,471
Open
49.71
Bid (Size)
50.60 (5)
Ask (Size)
50.85 (2)
Prev. Close
49.95
Today's Range
49.65 - 50.74
52wk Range
39.35 - 62.00
Shares Outstanding
2,222,113,553
Dividend Yield
4.51%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Today 15:12 EDT
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
September 02, 2024
Rebounding growth could make shares of this leading drugmaker a big winner.
Via
The Motley Fool
Performance
YTD
-4.25%
-4.25%
1 Month
+6.16%
+6.16%
3 Month
+21.01%
+21.01%
6 Month
-2.51%
-2.51%
1 Year
-16.69%
-16.69%
More News
Read More
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
September 01, 2024
Via
The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
September 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Market Whales and Their Recent Bets on BMY Options
August 27, 2024
Via
Benzinga
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
August 22, 2024
Via
Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
August 21, 2024
Via
Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 30, 2024
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Via
Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
August 28, 2024
Via
Benzinga
Check Out What Whales Are Doing With BMY
August 16, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
Via
Investor's Business Daily
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
August 28, 2024
Via
The Motley Fool
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
August 28, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Via
Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
August 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
August 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
August 20, 2024
Via
The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
August 18, 2024
Via
The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
August 18, 2024
Via
The Motley Fool
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.